OnBioVC continues to illuminate a deeply concerning financing trend observed over the last several years of aggregated data; one may term the resultant effect of this discernable development as an erosion in U.S.-based biomedical innovation. The metric invoked to quantify such bold nomenclature is simply the decline in first-time, Series A, institutional financings. With fewer [...]

• 812http://clsdf.com/2011/10/onbiovc-state-of-the-state-%e2%80%a6-sound-the-alarms/OnBioVC+%7C+State+of+the+State+%E2%80%A6+Sound+the+Alarms%212011-10-10+13%3A49%3A16admin

[Update #3] This is fast becoming perhaps my favorite post to update because it is the catalytic properties of the sometimes elusive to isolate GREEN enzyme that can enable so much good. That said, today’s new fund to report on, Mission Bay Capital (no website, yet…), though small in size, it is a seed fund [...]

• 556http://clsdf.com/2009/10/update-3-looking-for-some-more-of-this/UPDATE+%233+%7C+Looking+for+Some+%28MORE%29+of+This%3F2009-10-28+14%3A36%3A33admin